Claims for Patent: 5,618,702

Summary for Patent: 5,618,702

Title:	PCR amplification of mRNA
Abstract:	A method for producing a contaminating DNA free PCR amplification product of mRNA is disclosed. The mRNA amplification product is of lower molecular weight and is readily separated, e.g., by gel electrophoresis, from any amplified cellular DNA contaminant.
Inventor(s):	Scanlon; Kevin J. (Pasadena, CA)
Assignee:	City of Hope (Duarte, CA)
Application Number:	08/102,946
Patent Claims:	1. A method for producing a substantially contaminating DNA free PCR amplification product of a mRNA from a cellular DNA contaminated gene transcript, the method comprising: (a) providing a gene transcript mRNA, said gene having an intron flanked by first and second exons, said gene transcript mRNA being contaminated with template DNA from which said mRNA was transcribed, said mRNA having a first portion complementary only to a sequence of said first exon and an abutting second portion complementary only to a sequence of said second exon; (b) providing first and second PCR primers, said first PCR primer being complementary to said first portion of said mRNA and, said second PCR primer being complementary to the completment of said abutting second portion of said mRNA; (c) annealing said primers to said mRNA and thereafter, (d) reacting said mRNA having said primers anealed thereto with reverse transcriptase to provide double stranded DNA, one strand of which has the sequence of said mRNA and the other strand of which is complementary to said sequence of said mRNA; (e) reacting said double stranded DNA with said first and second primers in a PCR to simultaneously amplify (i) said double stranded DNA and (ii) said DNA contaminant to provide an amplification reaction product containing amplified double stranded DNA which has no sequence complementary to said intron and amplified DNA contaminant which includes said intron, wherein said amplified double stranded DNA which has no sequence complementary to said intron is of substantially lower molecular weight than said amplified DNA contaminant which includes said intron; and (f) utilizing the difference in molecular weights to separate said amplified double stranded DNA from said amplified DNA contaminant to produce a substantially contaminating DNA free PCR amplification product. 2. A method as defined by claim 1 in which said gene transcript is a transcript of a human oncogene. 3. A method as defined by claim 1 in which said gene transcript is a transcript of a human H-ras oncogene or a human c-myc oncogene or a human thymidylate synthase gene. 4. A method as defined by claim 1 in which said gene transcript is a transcript of a human c-myc gene. 5. A method as defined by claim 1 in which said transcript gene is a transcript of a human c-myc gene, said first primer has the sequence of SEQ ID NO: 1 and said second primer has the sequence of SEQ ID NO: 2. 6. A method as defined by claim 1 in which said gene transcript is a transcript of a human H-ras oncogene. 7. A method as defined by claim 1 in which said transcript gene is a transcript of a human H-ras gene, said first primer has the sequence of SEQ ID NO: 4 and said second primer has the sequence of SEQ ID NO: 5.

Details for Patent 5,618,702

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-04-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-04-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-04-08